哮喘變應(yīng)原免疫治療現(xiàn)狀與思考蘇州九龍醫(yī)院倪殿濤_第1頁
哮喘變應(yīng)原免疫治療現(xiàn)狀與思考蘇州九龍醫(yī)院倪殿濤_第2頁
哮喘變應(yīng)原免疫治療現(xiàn)狀與思考蘇州九龍醫(yī)院倪殿濤_第3頁
哮喘變應(yīng)原免疫治療現(xiàn)狀與思考蘇州九龍醫(yī)院倪殿濤_第4頁
哮喘變應(yīng)原免疫治療現(xiàn)狀與思考蘇州九龍醫(yī)院倪殿濤_第5頁
已閱讀5頁,還剩44頁未讀 繼續(xù)免費(fèi)閱讀

下載本文檔

版權(quán)說明:本文檔由用戶提供并上傳,收益歸屬內(nèi)容提供方,若內(nèi)容存在侵權(quán),請進(jìn)行舉報(bào)或認(rèn)領(lǐng)

文檔簡介

哮喘變應(yīng)原免疫治療現(xiàn)狀與思考蘇州九龍醫(yī)院倪殿濤Typesofallergies2021/4/272Allergen

Any

substance

often

a

protein

that

induces

an

allergy

Commonallergens過敏原種類很多“除了水、葡萄糖和鹽之外都可以成為過敏原”2021/4/273Commoncoldorallergy2021/4/274AsthmaDerivedfromtheGreekrootασθμαινωOriginallydidnotdefineadisease,butwasemployedtodescriberespiratorysymptomsofavarietyofpulmonaryconditionsBythebeginningofthe20thcentury,

asthma

wasseentobeauniqueillnesscharacterizedby'spasmodicafflictionsofthebronchialtubes'.Today,

asthma

isseenasachronicinflammatorydiseasewhichisnotyetfullyunderstoodinitspathophysiologyTherapyisstillonthepathtobecomingoptimal.BergmannKC.Asthma.ChemImmunolAllergy.2014;100:69-80.2021/4/275盲人摸象2021/4/2762014GINA哮喘表型Allergicasthma:usuallyrespondwelltoinhaledcorticosteroid(ICS)treatmentNon-allergicasthma:oftenrespondlesswelltoICS.Late-allergicasthma:someadults,particularlywomen,patientwithasthmaforthefirsttimeinadultlife.Thesepatientstendtobenon-allergic,andoftenrequirehigherdosesofICSorarerelativelyrefractorytocorticosteroidtreatmentAsthmawithfixedairflowlimitation:somepatientswithlong-standingasthmadevelopfixedairflowlimitationthatisthoughttobeduetoairwaywallremodeling.Asthmawithobesity:someobesepatientswithasthmahaveprominentrespiratorysymptomsandlittleeosinophilicairwayinflammation.GINAGuidelinesforAsthma20142021/4/277Terminologyofallergicphenomena'idiosyncrasy'-'antipathy'-'Hypersensitivity'-'Anaphylaxis'-'allergyA.F.CocaandR.A.Cookeintroducedtheterm'atopy':'hypersensitiveness'occurredspontaneously'atopy'gainedanewsense,sinceIgEisacharacteristic-Clinicallysimilardiseasessuchasasthma,rhinoconjunctivitisoreczemacanbefoundintheabsenceofIgE,andarethencalled'intrinsic'variantsofthesamediseaseChemImmunolAllergy.2014;100:46-52.2021/4/278CoombsandGell’sClassificationofHypersensitivity2021/4/279Does"intrinsic"asthmaexist?Tentofortypercentofasthmaticsare"intrinsic"Analysisofbronchialmucosalexpressionof"pro-eosinophilic"and"pro-atopic"markers[IL-3,-4,-5,-13,GM-CSF,RANTES,MCP-3,IgEandhighaffinityIgEreceptor(FcepsilonRI)]ThereweremoresimilaritiesthandifferencesinimmunopathologybetweenatopicandnonatopicHumbertM.Does"intrinsic"asthmaexist?RevMalRespir.2000Feb;17(1Pt2):245-54..2021/4/2710Allergicvsnonallergicasthma:

whatmakesthedifference?Nonallergic:Greaterage,femalesex,sinusalpolyposis,andFEV1below80%ofthepredictedvalueAllergic:historyofhayfever,seasonalexacerbationofasthma,andasthmadurationAllergy.2002Jul;57(7):607-13.2021/4/2711Asthmaphenotypes:nonallergic(intrinsic)asthma.Thedefinition:subjectswithasthmaandwithwhomallergicsensitizationcannotbedemonstratednegativeskinpricktestorinvitrospecific-IgEtesttoapanelofseasonalandperennialallergensNonallergicasthmaoccursin10%to33%ofindividualswithasthmaandhasalateronsetthanallergicasthma,withafemalepredominance.NonallergicasthmaappearstobemoreseverethanallergicasthmainmanycasesandmaybelessresponsivetostandardtherapyPetersSP.Asthmaphenotypes:nonallergic(intrinsic)asthma.JAllergyClinImmunolPract.

2014Nov-Dec;2(6):650-2..2021/4/2712Noveldiagnosticapproachesandbiologicaltherapeuticsforintrinsicasthma.ControversieshaveemergedinrelationtothisconceptNotfindingspecificallergensensitizationinanasthmaticpatientneitherexcludesanallergiccomponentnortheessentialrolethatimmunoglobulinEmayplayinasthmaTheatopicstatusisoneamongmanyotherquestionsOmalizumab,theonlymonoclonalanti-immunoglobulinEantibodycommercializedforasthma,shouldbetriedinpatientswithuncontrolledsevereasthmaindependentoftheiratopicstatus

VenneraMdelC1,

PicadoC1.Noveldiagnosticapproachesandbiologicaltherapeuticsforintrinsicasthma.IntJGenMed.

2014

Jul8;7:365-71.2021/4/2713哪些哮喘患者需要行AIT?過敏的概念總tIgE2021/4/2714SentietalAllergy2011;66(6):7981911Noon1thSCIT1950s1thSCITControlStudy;1980s1thDBPCSLIT;2000s1thsublingualTablet2011sInnovatingforpatientbenefit100yeasofantigenspecificimmunotherpy2021/4/2715Allergenspecificimmunotherapy2021/4/2716Self-amplificationmechanismsofmastcellactivation:

anewlookinallergy.Thecurrentdefinitionofallergy,agroupofIgEmediateddiseasesappearsdifficulttocoverallallergicreactionsSinceevenIgEdependentallergicreactionsarecarriedoutthroughactivationofmastcellsandbasophils,andallallergensmentionedabovecanactivatethesecellswehypothesizethatallergicreactionsaremastcellandbasophilmediatedinflammatoryprocessasitistheactivatedmastcellsandbasophilsthatinitiatethepathologicalprocessoftheimmediateallergicreactionswhereas

IgEonlyservesasoneoftheactivatorsofthesecells.HeS,ZhangH,ZengX,YangP.CurrMolMed.2012Dec;12(10):1329-39.2021/4/27172021/4/2718過敏性疾病實(shí)驗(yàn)室診斷的理想程序皮試、斑貼試驗(yàn)↓(陽性)過敏原、半抗原或小分子物質(zhì)↓嗜堿性粒細(xì)胞/肥大細(xì)胞激發(fā)試驗(yàn) ↓(陽性)(陰性基本排除急性過敏)

特異性IgE、IgG檢測

(陰性)

(陽性)

(陽性)

類過敏反應(yīng)IgE依賴性IgG依賴性

(目前定義為過敏)(目前定義為食物不耐受)

避免接觸類過敏原

↓↓(IgG陽性)

脫敏療法的適應(yīng)癥低敏食物、食物脫敏?2021/4/2719AIT適應(yīng)癥--中國專家共識2021/4/2720AIT禁忌癥-中國專家共識2021/4/2721哮喘患者AIT現(xiàn)狀2021/4/27222021/4/2723結(jié)論2021/4/27242021/4/2725SublingualimmunotherapyIncluded5,131patientsfrom63studieswereanalyzedthatsublingualimmunotherapyimprovessymptomsofasthmareducestheuseofasthmamedicationsimprovesthequalityoflifeLinetal.Sublingualimmunotherapyforthetreatmentofallergicrhinoconjunctivitisandasthma:asystematicreview.JAMA2013;309:1278-882021/4/27262021/4/27272021/4/2728AIT的安全性2021/4/2729哮喘AIT困惑與思考2021/4/2730過敏原識別過敏原的特異性診斷查找過敏原是與其他學(xué)科的基本區(qū)別2021/4/2731IgE介導(dǎo)變態(tài)反應(yīng)的診斷AllergicrhinitisanditsimpactonasthmaAllergy,2008,s1-153.2021/4/2732體內(nèi)試驗(yàn)-皮膚試驗(yàn)皮內(nèi)試驗(yàn)I型速發(fā)性變態(tài)反應(yīng)點(diǎn)刺試驗(yàn)I型速發(fā)性變態(tài)反應(yīng)斑貼試驗(yàn)IV型遲發(fā)型變態(tài)反應(yīng)2021/4/2733常用過敏原點(diǎn)刺液種類螨屬:戶塵螨、粉塵螨、熱螨、倉儲螨寵物毛發(fā)皮屑:貓毛、狗毛樹木花粉:榿木、榛屬、楊屬、榆科、柳屬、懸鈴木雜草花粉:蒿草、豚草、葎草、雞足草、酥油草、毒麥、梯牧草、牧場草作物花粉:向日葵、玉米真菌:鏈格孢、毛殼菌、芽枝霉、鐮刀菌、青霉、擴(kuò)展青霉、點(diǎn)青霉蟑螂:德國小蠊、美洲大蠊2021/4/2734體外試驗(yàn)-sIgE檢測嚴(yán)重皮炎不能作皮試者皮試假陽性的劃痕癥患者皮膚反應(yīng)差的老年人及3歲以下兒童用藥的影響嚴(yán)重過敏狀態(tài)發(fā)作者對作皮試時(shí)產(chǎn)生的不適恐懼者對過敏嚴(yán)重度評估擬行特異性免疫治療者2021/4/2735我國過敏原體外診斷種類RAST-放射過敏原吸附試驗(yàn)FEIA-固相熒光酶免疫技術(shù)(CAP)免疫印跡技術(shù)(AS)ELISA-酶聯(lián)免疫吸附試驗(yàn)免疫捕獲法(酶聯(lián)免疫吸附試驗(yàn)中之一種)過敏原芯片:固相/液相免疫化學(xué)發(fā)光法過敏原誘發(fā)組胺釋放試驗(yàn):期望能解決IgE不能解決的問題2021/4/2736五種免疫球蛋白的血漿濃度

(mg/dL)IgG1200(40000)IgM150(5000)IgA300(10000)IgD3(100)IgE0.03(1)血中IgE含量甚微,僅為血中IgG的四萬分之一特異性IgE含量則更甚微2021/4/2737一般的免疫學(xué)方法測不到sIgE放射過敏原吸附試驗(yàn)(RAST)

熒光免疫標(biāo)記分析法ELISA(酶聯(lián)免疫吸附測定)蛋白芯片檢測熒光酶免法(ImmunoCAPSweden)是檢測的金標(biāo)準(zhǔn)2021/4/2738總IgE的意義總IgE沒有正常值,只定上限端值,兒童50KU/L成人60KU/L新生兒的總IgE很低,隨年齡增長升高,10-15歲達(dá)頂峰,以后又逐步下降,男性高于女性理想的情況下,總IgE應(yīng)該是0或極低2021/4/2739

溫馨提示

  • 1. 本站所有資源如無特殊說明,都需要本地電腦安裝OFFICE2007和PDF閱讀器。圖紙軟件為CAD,CAXA,PROE,UG,SolidWorks等.壓縮文件請下載最新的WinRAR軟件解壓。
  • 2. 本站的文檔不包含任何第三方提供的附件圖紙等,如果需要附件,請聯(lián)系上傳者。文件的所有權(quán)益歸上傳用戶所有。
  • 3. 本站RAR壓縮包中若帶圖紙,網(wǎng)頁內(nèi)容里面會有圖紙預(yù)覽,若沒有圖紙預(yù)覽就沒有圖紙。
  • 4. 未經(jīng)權(quán)益所有人同意不得將文件中的內(nèi)容挪作商業(yè)或盈利用途。
  • 5. 人人文庫網(wǎng)僅提供信息存儲空間,僅對用戶上傳內(nèi)容的表現(xiàn)方式做保護(hù)處理,對用戶上傳分享的文檔內(nèi)容本身不做任何修改或編輯,并不能對任何下載內(nèi)容負(fù)責(zé)。
  • 6. 下載文件中如有侵權(quán)或不適當(dāng)內(nèi)容,請與我們聯(lián)系,我們立即糾正。
  • 7. 本站不保證下載資源的準(zhǔn)確性、安全性和完整性, 同時(shí)也不承擔(dān)用戶因使用這些下載資源對自己和他人造成任何形式的傷害或損失。

評論

0/150

提交評論